BMT Tandem "Scientific" Meeting
Harbor Ballroom ABC (Manchester Grand Hyatt)
Chairs:
John R. Wingard, MD
and
Sung Won Choi, M.D.
Disclosures:
J. R. Wingard,
Nothing To Disclose
S. W. Choi,
Nothing To Disclose
More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors
Jo-Anne H. Young, MD, University of Minnesota;
Brent R. Logan, PhD, Medical College of Wisconsin;
Juan (Maggie) Wu, MS, The EMMES Corporation;
John R. Wingard, MD, University of Florida;
Daniel J. Weisdorf, MD, University of Minnesota Medical Center;
Cathryn Mudrick, MPH, The EMMES Corporation;
Kristin Knust, MS, The EMMES Corporation;
Mary M. Horowitz, MD, MS, CIBMTR and Medical College of Wisconsin;
Dennis L. Confer, MD, National Marrow Donor Program;
Claudio Anasetti, MD, H. Lee Moffitt Cancer Center and Research Institute
Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: An Update from the International Compassionate Use Program in 710 Patients
Selim Corbacioglu, MD, University of Regensburg;
Enric Carreras, MD, PhD, Josep Carreras Foundation & Research Institute;
Mohamad Mohty, MD, PhD, Hopital Saint-Antoine;
Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, King's College Hospital;
Maria Ballabio, MD, Gentium S.p.A.;
Robin Hume, MS, Jazz Pharmaceuticals, Inc.;
Valeria Bandiera, Gentium S.p.A.;
Giorgia Finetto, Gentium S.p.A.;
Paul G. Richardson, MD, Dana-Farber Cancer Institute
Preliminary Results from the AdVise Study Evaluating Brincidofovir (CMX001, BCV) for the Treatment of Disseminated and High-Risk Adenovirus (AdV) Infection
Michael S. Grimley, MD, Cincinnati Children's Hospital Medical Center;
Gabriela M. Marón, MD, St. Jude Children's Research Hospital;
Vinod K. Prasad, MD, Duke University Medical Center;
David A. Jacobsohn, MD, Children's National Medical Center;
Jo-Anne H. Young, MD, University of Minnesota;
Greg Chittick, Chimerix, Inc.;
Thomas M. Brundage, MS, Chimerix, Inc.;
Hervé Momméja-Marin, MD, Chimerix, Inc.
Updated Results from the Ongoing US Treatment IND Study Using Defibrotide for Patients with Hepatic Veno-Occlusive Disease
Paul G. Richardson, MD, Dana-Farber Cancer Center, Harvard Medical School;
Angela R. Smith, MD, MS, University of Minnesota;
Brandon M. Triplett, MD, St Jude Childrens Research Hospital;
Nancy A. Kernan, MD, Memorial Sloan Kettering Cancer Center;
Stephan A. Grupp, MD, PhD, Children's Hospital of Philadelphia;
Sally Arai, MD, Stanford University Medical Center;
Joseph H. Antin, MD, Dana-Farber Cancer Institute, Harvard Medical School;
Leslie E. Lehmann, MD, Dana-Farber Cancer Institute, Harvard Medical School;
Valeria Bandiera, Gentium S.p.A.;
Robin Hume, MS, Jazz Pharmaceuticals, Inc.;
Alison Hannah, MD, Jazz Pharmaceuticals, Inc.;
Bijan Nejadnik, MD, Jazz Pharmaceuticals, Inc.;
Robert J. Soiffer, MD, Dana-Farber Cancer Institute, Harvard Medical School;
the Defibrotide Study Group, Gentium S.p.A.
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival
Paul G. Richardson, MD, Dana-Farber Cancer Institute;
Nancy A. Kernan, MD, Memorial Sloan Kettering Cancer Center;
Stephan A. Grupp, MD, PhD, Children's Hospital of Philadelphia;
Paul L. Martin, MD, PhD, Duke University Medical Center;
Robert J. Soiffer, MD, Dana-Farber Cancer Institute;
Richard Martin, MBChB, EUSA Pharma (an international division of Jazz Pharmaceuticals, plc);
Alison Hannah, MD, Jazz Pharmaceuticals, Inc.;
Kathleen F. Villa, MS, Jazz Pharmaceuticals, Inc.
Human Metapneumovirus Infections in Hematopoietic Cell Transplant Recipients: Seasonality and Factors Associated with Progression to Lower Respiratory Tract Disease
Sachiko Seo, MD, PhD, Fred Hutchinson Cancer Research Center;
Ted Gooley, PhD, Fred Hutchinson Cancer Research Center;
Jane M Kuypers, PhD, University of Washington;
Zach Stednick, MPH, Fred Hutchinson Cancer Research Center;
Keith R Jerome, MD, PhD, University of Washington;
Janet A Englund, MD, Seattle Children's Hospital;
Michael J. Boeckh, MD, Fred Hutchinson Cancer Research Center
Fibrinogen-Coated Nanospheres Prevent Thrombocytopenia-Related Bleeding
Anthony D. Sung, MD, Duke University Medical Center;
Richard Yen, MD, Fibroplate Inc.;
Divino Deoliveira, Duke University Medical Center;
Yiqun Jiao, MD, Duke University Medical Center;
Sadhna Piryani, Duke University Medical Center;
Alyssa Bernanke, Duke University Medical Center;
Sharon Hall, Duke University Medical Center;
Keith Klemp, Duke University Medical Center;
Sangwon Yun, Duke University Medical Center;
Gowthami Arepally, MD, Duke University Medical Center;
Maureane R Hoffman, MD, PhD, Duke University Medical Center;
Thomas L. Ortel, MD, PhD, Duke University Medical Center;
Nelson J. Chao, MD, MBA, Duke University Medical Center;
Benny J Chen, MD, Duke University Medical Center
Ex Vivo Expanded Multi-Specific Cytotoxic T Lymphocytes Derived from HIV+ Patients and HIV Negative Donors Using GMP Compliant Methodologies Recognize Multiple HIV Antigens and Suppress HIV Replication
Sharon Lam, Children's National Medical Center;
Julia A.M. Sung, M.D., University of North Carolina-Chapel Hill;
Russell Cruz, MD, PhD, Children's National Medical Center;
Paul Castillo, M.D., Baylor College of Medicine - Cell and Gene Therapy Center - Texas Children's Hospital;
Minthran Ngo, PhD, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital;
Joann Kuruc, University of North Carolina-Chapel Hill;
Cliona M. Rooney, PhD, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital;
David A. Margolis, MD, PhD, University of North Carolina-Chapel Hill;
Catherine M. Bollard, MD, Children's National Medical Center
![[Visit Client Website]](images/banner.gif)